Financials data is unavailable for this security.
View more
Year on year Pulike Biological Engineering Inc had relatively flat revenues (1.23bn to 1.25bn), though the company grew net income 3.99% from 167.82m to 174.52m. A reduction in the selling, general and administrative costs as a percentage of sales from 39.01% to 36.65% was a component in the net income growth despite flat revenues.
| Gross margin | 60.15% |
|---|---|
| Net profit margin | 11.68% |
| Operating margin | 12.61% |
| Return on assets | 4.07% |
|---|---|
| Return on equity | 4.83% |
| Return on investment | 4.77% |
More ▼
Cash flow in CNYView more
In 2023, Pulike Biological Engineering Inc increased its cash reserves by 14.89%, or 40.40m. The company earned 282.78m from its operations for a Cash Flow Margin of 22.57%. In addition the company used 1.66m on investing activities and also paid 241.03m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 7.65 |
|---|---|
| Tangible book value per share | 6.79 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.70 |
|---|---|
| Quick ratio | 2.26 |
| Total debt/total equity | 0.0129 |
|---|---|
| Total debt/total capital | 0.0127 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share increased 100.00% while earnings per share excluding extraordinary items fell by -3.93%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 1.75% |
|---|---|
| Div growth rate (5 year) | 18.47% |
| Payout ratio (TTM) | 105.59% |
| EPS growth(5 years) | 3.60 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -40.73 |
More ▼
